Here are four points:
1. The two companies plan to combine their cellular and biologic expertise to create a transformational regenerative medicine solution.
2. The initiative will work on complex regenerative solutions by researching ways to reprogram cells in damaged tissues.
3. The medical costs associated with spinal cord injury exceed $20 billion every year in the United States.
4. “The ability to merge cellular and biologic approaches represents the next evolutionary step in achieving complete regeneration and full functionally in this devastating disease,” said Dr. Himanshu Bansal, managing director, Revita Life Sciences.
More articles on spine:
Orthobiologics in spinal fusion: 5 key notes on outcomes for Cerapedics’ i-FACTOR
Dorsal lumbar fusions: 5 things to know about how BMP affects cost
Drs. Juan Ronderos, Victor Perry & more: 8 spine, neurosurgeons in the headlines this week
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
